Breast carcinoma with 21-gene recurrence score lower than 18: Rate of locoregional recurrence in a large series with clinical follow-up

The 21-gene recurrence score (RS) assay determines the benefit of adding chemotherapy to endocrine therapy for patients with early stage, estrogen receptor (ER)-positive, HER2-negative breast cancer.